AstraZeneca Pharmaceuticals LP
About AstraZeneca Pharmaceuticals LP
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
YEAR FOUNDED:
1999
LEADERSHIP:
CEO: Pascal Soriot
CFO: Marc Dunoyer
CMO: Marc Dunoyer
CTO: Andrew Chen
CCO: Katarina Ageborg
CMO: Sean Bohen
CLINICAL TRIAL:
Please click here for clinical trial information.
JOB OPPORTUNITY:
Please click here for AstraZeneca job opportunities.
PRODUCTS:
AstraZeneca Medications
For more information, visit
www.astrazeneca.com and follow us on www.twitter.com/astrazeneca.
FOLLOW AstraZeneca:
Tweets by AstraZeneca
What Science Can Do
2025 articles with AstraZeneca Pharmaceuticals LP
-
Although that is good news, cancer is the second-most common cause of death in the U.S., with more than 1.7 million new cancer cases each year and more than 600,000 cancer deaths. The report notes that one of the biggest factors in decreased cancer rates are lower tobacco smoking rates.
-
Luye Pharma Reaches Strategic Partnership with AstraZeneca, Strengthens Commitment to Cardiovascular Therapeutic Field
1/16/2019
Luye Pharma grants AstraZeneca exclusives rights to promote Xuezhikang Capsules in mainland China
-
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
-
It didn’t take long for the new leadership structure in the U.S. House of Representatives to take on the pharmaceutical industry. On Monday, the House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.
-
After four years at AstraZeneca, Chief Medical Officer Sean Bohen will be leaving the company following an organizational shakeup at the U.K.-based pharma giant. Bohen joined AstraZeneca from Genentech in 2015 and also serves as head of global medicines development.
-
BioSpace Movers and Shakers: Jan. 11
1/11/2019
Biopharma companies strengthen the leadership teams during the annual J.P. Morgan Healthcare Conference. -
AstraZeneca has indicated it plans to lay off 210 people in Boulder and Longmont. The reason is the company is consolidating “the biologics manufacturing network in one large-scale drug substance facility” in Frederick, Maryland.
-
With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing investors about pipeline advances. BioSpace snagged some of the interesting news bits to come out of the conference from Wednesday.
-
Biotech and pharma companies came roaring out of the gate on the first day of the annual J.P. Morgan Healthcare Conference with big deals, expansions and promises of growth and pipeline sustainability.
-
Baselga resigned from Memorial Sloan Kettering following reports he failed to disclose his financial ties to various pharma companies in articles he published.
-
LYNPARZA® (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer
12/20/2018
AstraZeneca and Merck’s LYNPARZA Significantly Improved Objective Response Rate Compared to Chemotherapy in Platinum-Sensitive Relapsed Patients Who Had Two or More Prior Lines of Chemotherapy
-
Phase III OLYMPUS and ROCKIES Trials for roxadustat Met Their Primary Endpoints in Chronic Kidney Disease Patients With Anemia
12/20/2018
OLYMPUS demonstrated a statistically-significant and clinically-meaningful improvement in hemoglobin vs. placebo in non-dialysis-dependent patients
-
An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.
-
Merck & Co. found itself with two new approvals this week. The FDA approved Lynparza (codeveloped by AstraZeneca and Merck) and also approved Merck's Keytruda. Both of these drugs were approved for new indications.
-
AstraZeneca released data from two clinical trials of roxadustat in anemia and of its trial of Lynparza in ovarian cancer. All the trials had positive results.
-
Although every year, big biopharma companies give up on some programs, 2018 seems like it has been marked by unusually extensive program abandonment.
-
AstraZeneca Healthcare Foundation Awards over $1.16 Million to 11 Innovative Heart Health Programs
12/11/2018
Eleven community-based heart health programs with innovative approaches to help prevent and control heart disease received grants totaling over $1.16 million from the AstraZeneca HealthCare Foundation’s Connections for Cardiovascular HealthSM program.
-
AstraZeneca and Cancer Research UK launch Functional Genomics Centre to accelerate the discovery of new medicines
12/10/2018
Centre of excellence will use CRISPR technology, big data and clinical insights to discover new targets and disease pathways in oncology Separate collaborations with Wellcome Sanger Institute and Innovative Genomics Institute aim to identify novel drug targets in oncology using CRISPR technology
-
AstraZeneca and its MedImmune division announced results from its Phase III EAGLE clinical trial. Imfinzi, in combination with tremelimumab, an anti-CTLA4 antibody, compared to standard-of-care (SoC) chemotherapy, failed to meet its primary endpoints in patients with recurrent or metastatic head ...
-
The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.